FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients

FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients

Stacy Arnold Stacy Arnold

Stacy Arnold

Senior Executive R&D, Clinical, PMO | Board member

发布日期: 2016年3月14日
+ 关注

U.S. FDA Grants Expanded Labeling Claim to On-X Life Technologies, Reducing Blood-Thinning Requirements for Heart Valve Patients | Business Wire

While the AHA-ACC guidelines generally recommend an INR target in the range of 2.0 to 3.0, patients who receive On-X Aortic Heart Valves with reduced anticoagulation medication levels should experience the added benefits of an enhanced quality of life along with diminished overall risk of medication-related bleeding complications.”

Stuart C.

Director at e3 Consultancy Ltd

9 年

Life changing news for all those On-X implantees currently managing their anti-coagulation!

赞
回复

要查看或添加评论，请登录

Stacy Arnold的更多文章

社区洞察

其他会员也浏览了